Floatz logo

Dordaviprone

Malignant Ovarian Epithelial Tumor

Ira WinerSmall moleculePhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Malignant Ovarian Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Wake Forest University Health Sciences
Phase 2BB
Niraparib
CanariaBio Inc.
Phase 2CCC
Trientine
National Cheng-Kung University Hospital
Phase 1/2CCC
Inno-206
National Cheng-Kung University Hospital
Phase 1/2CCC
Avelumab
University of Texas Southwestern Medical Center
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN CA125 (CARBOHYDRATE ANTIGEN)) (MOUSE MONOCLONAL B43.13.GAMMA.1-CHAIN), DISULPHIDE WITH MOUSE MONOCLONAL B43.13.KAPPA.-CHAIN, DIMER
CanariaBio Inc.
Phase 2CC

Same molecule, other indications

Dordaviprone is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →